CAPTRUST Financial Advisors’s Aquestive Therapeutics AQST Stock Holding History

CAPTRUST Financial Advisors’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$66.4K	Buy	+16,000	New	+$64.9K	﹤0.01%	2867

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

CAPTRUST Financial Advisors's AQST Position: Q1 2026 in Review

CAPTRUST Financial Advisors opened a new position in Aquestive Therapeutics (AQST) in Q1 2026: 16,000 shares worth $66.4K. The stake represents ﹤0.01% of the portfolio and ranks #2867 among its holdings.

179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

CAPTRUST Financial Advisors held 16,000 shares of Aquestive Therapeutics worth $66.4K as of Q1 2026.
Aquestive Therapeutics was a new CAPTRUST Financial Advisors position in Q1 2026.
Aquestive Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q1 2026, its #2867 holding.
179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.